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Objective: Leucine-rich glioma-inactivated 1 (LGI1) encephalitis is the second most common antibody-mediated
encephalopathy, but insight into the intrathecal B-cell autoimmune response, including clonal relationships, isotype dis-
tribution, frequency, and pathogenic effects of single LGI1 antibodies, has remained limited.
Methods: We cloned, expressed, and tested antibodies from 90 antibody-secreting cells (ASCs) and B cells from the
cerebrospinal fluid (CSF) of several patients with LGI1 encephalitis.
Results: Eighty-four percent of the ASCs and 21% of the memory B cells encoded LGI1-reactive antibodies, whereas
reactivities to other brain epitopes were rare. All LGI1 antibodies were of IgG1, IgG2, or IgG4 isotype and had under-
gone affinity maturation. Seven of the overall 26 LGI1 antibodies efficiently blocked the interaction of LGI1 with its
receptor ADAM22 in vitro, and their mean LGI1 signal on mouse brain sections was weak compared to the remaining,
non–ADAM22-competing antibodies. Nevertheless, both types of LGI1 antibodies increased the intrinsic cellular excit-
ability and glutamatergic synaptic transmission of hippocampal CA3 neurons in slice cultures.
Interpretation: Our data show that the patients’ intrathecal B-cell autoimmune response is dominated by LGI1 anti-
bodies and that LGI1 antibodies alone are sufficient to promote neuronal excitability, a basis of seizure generation.
Fundamental differences in target specificity and antibody hypermutations compared to the CSF autoantibody reper-
toire in N-methyl-D-aspartate receptor encephalitis underline the clinical concept that autoimmune encephalitides are
very distinct entities.
ANN NEUROL 2020;87:405–418
Limbic encephalitis associated with antibodies toleucine-rich glioma-inactivated 1 (LGI1)1,2 is the sec-
ond most common form of the growing number of
autoimmune encephalopathies (AIEs) with
autoantibodies targeting central nervous system
antigens.3–6 LGI1 encephalitis is characterized by gener-
alized and partial epileptic seizures, often as
faciobrachial dystonic seizures (FBDS),7 spatial
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disorientation, and amnesia, and it affects preferentially
50- to 70-year-old men. Epileptic activity could be detected
in frontal cortex as well as hippocampus of patients,3 and
magnetic resonance imaging (MRI) studies revealed marked
atrophy and impaired microstructural integrity of the hip-
pocampus, correlating with cognitive impairment.8 LGI1
antibodies are present in serum and cerebrospinal fluid
(CSF) of patients, and a recent study suggested that an
increased LGI1-IgG CSF index correlates with worse out-
come.9 Like many other autoimmune disorders, LGI1
encephalitis is associated with a defined genetic
predisposition.10–13
LGI1 is secreted by neurons as a 60kDa protein
containing leucine-rich repeat (LRR) and epitempin
(EPTP) repeat domains. It forms protein complexes
with ADAM22 and ADAM23 at excitatory synapses
and may actually link these two transmembrane pro-
teins across the synaptic cleft.14,15 LGI1 affects the
development of glutamatergic synapses via postsynaptic
density proteins like PSD-9514,16 and regulates neuro-
nal excitability through axonal Kv1.1 potassium chan-
nel complexes.17 Mutations in the LGI1 gene cause
autosomal dominant partial epilepsy with auditory fea-
tures (ADPEAF). Targeted deletion of Lgi1 in mice
resulted in lethal myoclonic epileptic seizures.18–20
CA3 neurons of Lgi1−/− hippocampal slice cultures
exhibited an increased intrinsic neuronal excitability
that may explain seizure generation.21
Acute application of IgG from sera of limbic
encephalitis patients increased the release probability of
mossy fibers and enhanced the excitability of CA3 neu-
rons in hippocampal slices.22 Furthermore, continuous
intraventricular infusion of such IgG preparations into
the CSF of mice enhanced glutamatergic neurotransmis-
sion by increasing presynaptic excitability in 2 path-
ways.23 Injection of human CSF containing LGI1
antibodies into the dorsal hippocampus of mice
increased both the probability of glutamate release from
CA3 neurons and the amplitude of population spikes in
the CA1 area following Schaffer collateral stimulation.24
Although immunosuppression is effective in 50 to 80%
of patients with LGI1 encephalitis,4 detailed insight into
the composition of the humoral autoimmune response
to LGI1 in the CSF and the role of single LGI1 anti-
bodies is missing. As exemplified by recent studies of N-
methyl-D-aspartate (NMDA) receptor encephalitis,
sequencing and expression of monoclonal antibodies
from patient samples allow a deeper understanding of
autoimmune encephalopathies.25,26 Here, we amplified
and cloned variable heavy and light chain sequences
from CSF-derived antibody-secreting cells (ASCs) and B
cells of 3 patients with LGI1 encephalitis. We expressed
85 monoclonal recombinant antibodies and character-
ized their reactivities and antigen-binding sites. Further-
more, we explored the effects of single recombinant
LGI1 antibodies on the intrinsic excitability of neurons
and on glutamatergic synaptic transmission.
Materials and Methods
Mammalian Expression Constructs
The cDNAs for amino acids 1 to 558 of human LGI1
(NM_005097.3), for amino acids 1 to 545 of human LGI2
(NM_018176.3), and for amino acids 1 to 400 of human
GluN1 (NM_007327) were inserted into pFuse-rIgG-Fc1
(InvivoGen, San Diego, CA). The resulting plasmids encode
human LGI1, human LGI2, and the aminoterminal domain
(ATD) of human GluN1, respectively, fused to the Fc region of
rabbit IgG (amino acids SKP-PGK) linked by amino acids
GSSTMVRS. The chimeric constructs LRR1-EPTP2 and
LRR2-EPTP1 encode rabbit Fc fusions of amino acids 1 to
223 of LGI1 and amino acids 218 to 545 of LGI2 or amino
acids 1 to 217 of LGI2 and amino acids 224 to 557 of LGI1,
respectively.
The cDNA for amino acids 32 to 727 of mouse ADAM22
N-terminally tagged with amino acids SWSQ was inserted into the
cytomegalovirus expression vector for IGL27,28 together with an
adaptor encoding a C-terminal hemagglutinin (HA) epitope. The
resulting plasmid encodes amino acids MGWSCIILFLVATA
TGSWSQ, the extracellular region of mouse ADAM22, and the
C-terminal amino acids ASYPYDVPDYA.
The cDNAs of rat LGI1 (AJ487517), mouse LGI2
(AY841361), rat LGI3 (NM_001107277), and mouse
ADAM22 (HM004095) were cloned by reverse transcription
and polymerase chain reaction (PCR) amplification as previ-
ously described14,19 and subcloned into cytomegalovirus
promoter-driven vectors.
Cloning and Expression of Immunoglobulins
from Patient CSF Cells
All clinical investigations were conducted according to Declara-
tion of Helsinki principles. Patients gave written informed con-
sent prior to inclusion in the study, and analyses were approved
by the Charité University Hospital Institutional Review Board.
Single cells were isolated from patients’ CSF samples using
fluorescence-activated cell sorting into 96-well PCR plates at the
Flow Cytometry Core Facility of the German Rheumatism
Research Center Berlin using the following gating strategy. T
cells, monocytes, and NK cells as well as nonviable cells were
excluded from preselected single lymphocytes by gating on
CD3−/CD14−/CD16−/DAPI− events. From the remaining cells,
we selected either CD138+ ASCs or CD20+ B cells. For B cells,
CD27 expression was used to differentiate between CD20+/
CD27+ memory B cells (MBCs) and CD20+/CD27− non-
memory B cells (NMBCs). The following antibodies were
applied: anti–CD3-FITC (1:25; Miltenyi Biotec, Bergisch
Gladbach, Germany; #130-098-162), anti–CD14-FITC (1:25,
Miltenyi Biotec, #130-098-063), anti–CD16-FITC (1:25,
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Miltenyi Biotec, #130-098-099), anti–CD20-PerCP-Vio700
(1:50, Miltenyi Biotec, #130-100-435), anti–CD27-APC-
Vio770 (1:12.5, Miltenyi Biotec, #130-098-605), and anti–
CD138-PE (1:50, Miltenyi, #130-098-122).
Cloning of antibody heavy and light chains from single
CSF cells,25,27,29 sequence analyses, and expression and purifica-
tion of antibodies were performed essentially as previously
described.25 Sequencing was performed at LGC Genomics
(Berlin, Germany). Antibodies were used for further analyses if
they yielded >2μg human IgG/ml. For antibodies not reaching
2μg human IgG/ml, the production was repeated.
Enzyme-Linked Immunosorbent Assay
96-well high-binding microplates (Greiner Bio-One Interna-
tional, Kremsmünster, Austria; #655061) coated with donkey
anti-rabbit IgG (10μg/ml; Dianova, Hamburg, Germany;
#711-005-152) were blocked and incubated with cell culture
supernatants of HEK293 cells that expressed Fc fusion con-
structs. Cell culture supernatants containing monoclonal anti-
bodies (mean  standard deviation of human IgG
concentrations: 10.7  5.6μg/ml) or purified antibodies and
horseradish peroxidase (HRP)-conjugated donkey anti-human
IgG (1:5,000, Dianova, #709-035-149) were sequentially
applied. After thorough washing, HRP activity was measured
using 1-Step Ultra TMB-ELISA substrate (Thermo Fisher Sci-
entific, Waltham, MA). The presence of immobilized antigens
was confirmed by incubation with HRP-conjugated F(ab0)2
donkey anti-rabbit IgG (1:50,000, Dianova, #711-036-152).
Human recombinant anti-GluN1 antibody 003-10225 was used
at 10ng/ml. Mouse monoclonal anti-LGI1 antibody, N283/7
(1:1,000), was obtained from the University of California,
Davis/NIH NeuroMab Facility.
Competition between LGI1 antibodies and ADAM22 for
LGI1 binding was evaluated by measuring binding of the HA-
tagged soluble extracellular domain of ADAM22 (ADAMexHA)
to LGI1 that had been preincubated with LGI1 antibodies at
1μg/ml for 15 minutes. Bound ADAMexHA was detected using
mouse anti-HA.11 (1:2,000; BioLegend, San Diego, CA;
#901515) and HRP-conjugated donkey anti-mouse IgG
(1:5,000, Dianova, #715-035-150).
Background by HRP-conjugated detection antibody alone
was subtracted from each value except for in Figure 1B.
Immunohistochemistry of Mouse Brain Sections
For screening of recombinant monoclonal antibodies, unfixed
20μm sagittal mouse brain cryostat sections were thawed, washed
with phosphate-buffered saline (PBS) and blocked (PBS sup-
plemented with 2% bovine serum albumin [Carl Roth, Karls-
ruhe, Germany] and 5% normal goat serum [Abcam,
Cambridge, MA]). Undiluted HEK293T cell supernatants con-
taining human monoclonal antibodies were applied overnight at
4C. After washing, sections were incubated with Alexa Fluor
488-conjugated goat anti-human IgG (1:1,000, Dianova,
#109-545-003) in blocking solution. Sections were washed again
and mounted with DAPI-containing Fluoroshield.
For costainings, sagittal mouse brain sections were fixed
with 4% paraformaldehyde (PFA) and incubated sequentially with
blocking solution containing additional 0.1% Triton X-100
(Chemsolute), with purified primary antibodies diluted to 5μg/ml
and chicken anti-MAP2 (1:1,000, Thermo Fisher Scientific,
#PA1-16751) and with Alexa Fluor 488-conjugated goat anti-
human IgG (1:1,000) and Alexa Fluor 568-conjugated goat anti-
chicken IgG (1:500; Invitrogen, Carlsbad, CA; #AB_2534098).
Immunohistochemistry of Wild-Type and Lgi1−/−
Mouse Brain Sections
All animal studies described herein were reviewed and
approved by the animal care committee of the National Insti-
tutes of Natural Sciences and were performed in accordance
with its guidelines. Ten-micrometer cryostat sections from
Lgi1−/− mice19 and their littermate controls (wild-type; postna-
tal day [P]17) were fixed with acetone, rehydrated, blocked in
PBS containing 10% donkey serum, and incubated with puri-
fied AB060-110 or AB060-203 (2μg/ml) and rabbit anti-Prox1
antibody (Abcam, ab11941; 1:500). Immunoreactions were
visualized by Cy3-conjugated anti-human IgG and Alexa
Fluor 488-conjugated anti-rabbit IgG secondary antibodies,
respectively.
Quantification of LGI1 Antibody Binding against
Brain Tissue
For relative quantification of the binding strength of LGI1 anti-
bodies, PFA-fixed mouse brain sections were stained with
HEK293T cell supernatants containing 5μg/ml of monoclonal
antibody and fluorescence intensity within the hippocampal CA3
region was quantified as described.30 After medium background
subtraction, fluorescence intensity values were put in relation to
the maximum value.
Cell-Based Binding Assay
COS7 cells expressing LGI family members and chimera on the
cell surface were stained with purified human antibodies
AB060-110 or AB060-203 (10μg/ml) and mouse FLAG M2
antibody (Sigma-Aldrich, St Louis, MO; #F3165, RRID:
AB_259529) as described.31
Electrophysiological Recordings in Organotypic
Slice Cultures
Animal husbandry and experimental intervention were per-
formed according to the German animal welfare act and the
European Council Directive 86/609/EEC regarding the protec-
tion of animals used for experimental and other scientific pur-
poses. All animal maintenance was performed in accordance with
the guidelines of local authorities (Berlin T 0100/03).
Hippocampal slice cultures were prepared from C57/Bl6N
mice (P5–9) as described.32 Antibodies were applied to the slices
at 13 to 14 days in vitro at 100nM final concentration, and
recordings were performed 24 to 48 hours later.
Prior to recording, slices were transferred to a submerged
recording chamber (Luigs and Neumann, Ratingen, Germany)
and perfused with oxygenated artificial CSF (ACSF; pH 7.4)
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FIGURE 1: An intrathecal B-cell immune response dominated by LGI1 antibodies. (A) Isolation of single antibody-secreting cells
(ASCs) as well as memory and nonmemory B cells (MBCs/NMBCs) from cerebrospinal fluid (CSF) of LGI1 encephalitis patients by
flow cytometry. FSC = forward scatter. (B) To screen for LGI1 reactivity, cell culture supernatants of HEK293T cells expressing
CSF cell-derived antibody cDNAs were applied to LGI1-Fc and to N-methyl-D-aspartate receptor subunit GluN1-ATD-Fc captured
on an enzyme-linked immunosorbent assay plate. Example assay shows results for 13 supernatants as well as controls including
CSF samples (diluted 1:5), human recombinant anti-GluN1, mouse anti-LGI1, and secondary antibodies to human, mouse, and
rabbit IgG alone. Signals are shown as mean + standard deviation of 2 wells. (C–G) LGI1 (red signal) was detected by human
recombinant antibody AB060-110 (5μg/ml) in the hippocampal formation (C), the neuropil of hippocampal area CA3 (D), the
molecular layer (ML) of the cerebellum (E), the cerebral cortex (F), and the striatum (G) on paraformaldehyde-fixed mouse brain
sections. Costained neuronal MAP2 is shown in green, nuclei (DAPI) in blue. CC, corpus callosum; CP, choroid plexus; CX,
cerebral cortex; GCL, granule cell layer; PCL, Purkinje cell layer; STR, striatum. (H) The majority of CSF-resident ASCs express
LGI1 antibodies. Left: distribution of cellular phenotypes of all cells with successfully expressed antibodies and of LGI1-reactive
cells (LGI1+) for each of the 3 patient samples. Variations in fluorescence-activated cell sorting settings/gate sizes account for
variable fractions of NMBCs between patients. Right: total numbers of ASCs, MBCs, and NMBCs. AIE = autoimmune
encephalitis. (I) LGI1-reactive antibodies were of the IgG1, IgG2 or IgG4 isotype. The distribution of isotypes is shown per
patient sample (left) and in all cells (right). (J) Antibody sequence analyses indicated individual clusters of clonally expanded cells
(Figure legend continues on next page.)
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containing (in mM) NaCl (119), NaHCO3 26, glucose 10, KCl
(2.5), NaH2PO4 (1.25), MgCl2 (4.0), and CaCl2 (4.0) at room
temperature, with a perfusion rate of 5ml/min. Excitability of
the cells was measured in current clamp mode with a K-gluco-
nate–based intracellular solution containing (in mM) K-
gluconate (120), Hepes 20, KCl 3, NaCl 7, MgATP 4, NaGTP
(0.3), and phosphocreatine 14, adjusted to pH 7.3 with KOH.
Membrane potential values were corrected for liquid junction
potential (−15mV). Membrane potential was manually adjusted
to −75mV by continuous somatic current injection. Membrane
response and action potential (AP) firing were measured by
applying depolarizing current steps (duration = 1 second, incre-
ment = 40pA). For input–output curves, the number of APs was
plotted with the injected current. The rheobase represents the
minimal current eliciting at least 1 AP; AP threshold refers to the
membrane potential at which an AP is triggered (5% of the maxi-
mal AP slope). The slope of the depolarizing ramp in current
clamp mode was calculated in a 0.7-second time window at the
current injection step before the rheobase. Cell capacitance and
input resistance were detected in current clamp configuration by
measuring the time constant τ and the voltage deflection of a hyp-
erpolarizing current pulse. For recordings with dendrotoxin-K
(DTX-K; 100nM), either the slices were preincubated for at least
24 hours or acute wash-in of the toxin was performed.
To isolate α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid receptor (AMPAR) miniature excitatory postsynaptic currents
(mEPSCs), 1μM tetrodotoxin, 1μM SR95531 (gabazine), and
50μM D-AP5 were added to the ACSF. Slices were preincubated
for 24 to 30 hours with antibodies or with DTX-K. Cells were
recorded in voltage clamp configuration and were clamped
to −70mV. mEPSC signals were detected automatically using
IGOR Pro (WaveMetrics, Lake Oswego, OR) with the plugin
Neuromatics and subsequently manually sorted by visual inspection.
Cumulative distribution of mEPSC amplitude and interevent
interval (IEI) were analyzed using an equal number of events per cell
per condition to prevent overrepresentation of single neurons. Only
cells where at least 10 IEIs could be detected were taken into
account for the distribution. Kolmogorov–Smirnov test was per-
formed to compare the distributions of individual conditions, and
Bonferroni correction for multiple comparison was performed to
adjust p-values.
Nonparametric 1-way analysis of variance (ANOVA)
(Kruskal–Wallis) and Dunn multiple comparison test were per-
formed to test significance in the different treatment conditions
unless otherwise stated.
Results
CSF Cell Analysis Reveals a Polyclonal Humoral
Immune Response with LGI1 as the Primary
Target in the Brain
We set out to sequence and clone immunoglobulins from
ASCs and B cells in the CSF of patients with LGI1
encephalitis following the strategy described previously for
NMDA receptor encephalitis.25 We used fluorescence-
activated cell sorting to isolate NMBCs (CD20+ CD27−),
MBCs (CD20+ CD27+), and ASCs (CD138+) from CSF
of 3 patients fulfilling diagnostic criteria for LGI1 enceph-
alitis with positive LGI1 autoantibodies (see Fig 1A). All
3 patients (AIE054, AIE060, and AIE137) showed charac-
teristic symptoms of LGI1 encephalitis, with behavioral
abnormalities, cognitive deficits, and seizures, and had
mesiotemporal hyperintensities on T2/fluid-attenuated
inversion recovery MRI (Table). At the time of CSF sam-
pling, all patients had already received antiepileptic treat-
ment and immunotherapy, which may have compromised
the CSF B-cell response. The cell counts and protein
levels from CSF were normal or slightly elevated, and only
1 of the patients had oligoclonal IgG bands present on
routine laboratory tests.
RNA from single cells was reverse-transcribed, and
the cDNAs encoding the variable regions for heavy and
light chains were amplified and sequenced (Supplementary
Table). The amplicons were cloned into IgG1 expression
vectors.27,28 The human antibodies were expressed in
HEK293T cells, and the cell culture supernatants were
tested for binding to a recombinant LGI1 fusion protein
in an enzyme-linked immunosorbent assay (ELISA; see
Fig 1B). Of 90 CSF cells, 29 encoded an LGI1-reactive
antibody (AIE054: 6/9 ASCs, 0/9 MBCs, and 0/19
(colored). Sample sizes (number of cells) are given on top of the bars. (K, L) Human CSF LGI1 antibodies carry high numbers of
somatic hypermutations (SHMs). The numbers of SHMs within the V gene segments of Ig heavy (IGH) chains (K) and of Ig kappa
(IGK) or lambda (IGL) light chains (L) are plotted for each antibody generated from ASCs and MBCs of Patients AIE054 and
AIE060 together with the mean ± standard error of the mean (SEM). In AIE054, LGI1-reactive antibodies (LGI1+) contained
higher numbers of SHMs than LGI1-negative (LGI1−) antibodies (unpaired t test, **p < 0.01; IGH: p = 0.0023; IGK/L: p = 0.0019,
n = 6 and 13), whereas the numbers of SHMs were comparable in LGI1-reactive antibodies and LGI1-negative antibodies in
AIE060 (IGH: p = 0.9381; IGK/L: p = 0.9991, n = 18 and 23). The number of antibodies generated from cells of AIE137 was too
low to be included in this analysis. IGHV = immunoglobulin heavy chain V gene segment; IGK/LV = immunoglobulin kappa or
lambda light chain V gene segment. (M–Q) Autoreactivities to unknown brain epitopes. Four of the human recombinant
antibodies derived from LGI1 encephalitis patients’ CSF cells showed clear reactivities to antigens other than LGI1 on unfixed
mouse brain sections. (M) AB054-141 stains specifically the inferior colliculus (IC) within the mesencephalon and large blood
vessels (arrow). CB, cerebellum. (N) AB060-108 is a weak LGI1-reactive antibody, but also highlights the choroid plexus.
(O) 060-176HL is reactive to glial fibers (arrows) in different brain regions, most prominent around the ventricular system. (P, Q)
060-144 binds to fine tracks within the white matter, explicitly in the cerebellum (P) and the anterior commissure (Q). Scale
bars = 100μm.
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NMBCs; AIE060: 11/12 ASCs, 7/28 MBCs, and 0/7
NMBCs; AIE137: 4/4 ASCs, 1/1 MBC, and 0/1
NMBC). A few cells encoded identical antibodies; when
excluded, the analysis resulted in 85 different antibodies,
26 of which bound to LGI1 in the ELISA and revealed
the typical extracellular LGI1 distribution on sagittal
mouse brain sections (see Fig 1C–G).
Over all 3 patients, 21 of 25 ASCs encoded anti-
bodies to LGI1, hinting at intrathecal synthesis of LGI1
antibodies as a dominant immune response (see Fig 1H).
In 2 of the patients’ CSF (AIE060, AIE137) we found
MBCs to encode LGI1 antibodies as well. Although not
actively secreting antibodies, these dividing cells can be a
long-lived source of further LGI1-specific ASCs.33 The
comparable number of somatic hypermutations (SHMs)
in LGI1-reactive antibodies derived from MBCs and
ASCs supports this idea. Thus, MBCs may be involved
in the development of an immunological memory within
the brain and could be relevant for the chronic progres-
sive nature of the disease. In Patient AIE137, 1 MBC
and 3 ASCs of 6 cells analyzed in total encoded an iden-
tical antibody to LGI1. In AIE054 and AIE060, we
detected a few cell clusters containing 2 ASCs and/or an
MBC and an ASC expressing antibodies related to LGI1
within a pool of cells with unique antibody sequences
(see Fig 1J). These data show a broad reactivity to LGI1
based on independent clones. Furthermore, the high fre-
quency of LGI1 antibodies, the clonal relation of differ-
ent B-cell and ASC populations, and the comparable
degree of antibody maturation in MBCs and ASCs in
the CSF suggest a chronic exposure to LGI1 and an
antigen-driven maturation within the central nervous
system.
LGI1 encephalitis is known to be caused primarily
by IgG4 antibodies.34,35 In accord, more than half of the
LGI1 antibodies cloned from Patient AIE060 were of the
IgG4 subclass (see Fig 1I). However, all 6 LGI1 anti-
bodies from Patient AIE054 belonged to the IgG2 sub-
class (see Fig 1I). Thus, the immunoglobulin subclass
composition can differ significantly between LGI1
encephalitis patients, and heterobispecific IgG4 LGI1 anti-
bodies may not be a requirement in all forms of LGI1
encephalitis.
In Patient AIE054, the total number of SHMs in
the respective heavy and light chain V genes was higher in
LGI1-reactive antibodies than in nonreactive antibodies
from ASCs or MBCs, indicating a selective antibody mat-
uration toward increased LGI1 reactivity (see Fig 1K, L).
In contrast, the number of SHMs in Patient AIE060 was
similar between LGI1-reactive and nonreactive antibodies.
The overall high number of SHMs in LGI1-reactive anti-
bodies expressed by CSF-resident cells supports the model
of intrathecal antigen-driven maturation of autoantibodies
in LGI1 encephalitis.
Most of the antibodies that tested negative in the
ELISA did not show any reactivity on mouse brain sec-
tions. With 4 of the 85 monoclonal antibodies, we
observed divergent patterns highlighting different neuronal
and glial structures (see Fig 1M–Q), indicating autoim-
munity toward brain antigens other than LGI1. Neverthe-
less, these data indicate that LGI1 is the predominant
target of antibodies produced in the brain of LGI1
encephalitis patients.
LGI1 Antibodies Interfering with the
LGI1-ADAM22 Interaction Are a Common
Feature of the Intrathecal B-Cell Autoimmune
Response
Previous studies revealed that most sera from LGI1
encephalitis patients compete with the ligand–receptor
interaction between LGI1 and ADAM22 in contrast to
sera from patients with the peripheral nerve disorder neu-
romyotonia containing autoantibodies to LGI1.23,31 Fur-
thermore, a serum competing with ADAM22 binding to
LGI1 induced a reversible reduction in synaptic AMPAR
clusters in neuronal cultures.31 This fostered the proposal
that interference with the LGI1–ADAM interaction may
be a pathogenic mechanism of LGI1 antibodies.
We therefore tested whether any of the 26 monoclonal
LGI1 antibodies identified in this screen interfered with the




























































































































FIGURE 2: Differential interference of isolated LGI1
antibodies with the interaction between ADAM22 and LGI1.
Enzyme-linked immunosorbent assay signals indicate binding
of the extracellular domain of ADAM22 (ADAMexHA) to
LGI1-Fc after 15-minute preincubation with cell culture
supernatants containing human monoclonal LGI1 antibodies
(adjusted to 1μg/ml human IgG). For each measurement, the
mean ADAMexHA signal from 2 wells was related to a
control without antibody. The means + standard deviation of
at least 3 measurements are presented for each antibody.
Results for AB054-146 and AB060-108 were excluded,
because their LGI1-binding was very weak under these
conditions.
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FIGURE 3: Human monoclonal antibodies AB060-110 and AB060-203 specifically recognize LGI1, but differ in their access to
native LGI1. (A) Signals for both AB060-110 and AB060-203 are undetectable on Lgi1−/− sections. For AB060-203, laser power
was increased from 24% to 50% during imaging, because the signal with AB060-203 was much weaker than the one with
AB060-110 (inset shows the signal at 24% laser power). Dentate gyrus stainings of wild-type and Lgi1−/− sections are shown
with human IgG and the granule cell marker Prox1 in red and green, respectively. GL = granule cell layer; ML = molecular layer;
PL = polymorphic layer. Scale bar = 20μm. (B) Similar concentration-dependent binding of recombinant LGI1 by AB060-110 and
AB060-203. Purified antibodies were applied at various concentrations to LGI1-Fc captured on an enzyme-linked immunosorbent
assay (ELISA) plate. Signals are shown as mean ± standard deviation (SD) from 3 wells. (C) Human monoclonal antibodies
AB060-110 and AB060-203 differentially detect LGI1/ADAM22 complexes. Immunocytochemical analysis on COS7 cells
expressing the proteins indicated in black on top of the images is shown. Bound human IgG and surface-expressed LGI-FLAG-
GPI are shown in red and green, respectively. Left: AB060-110 specifically recognized LGI1 irrespective of coexpressed
ADAM22. Right: AB060-203 specifically recognized recombinant LGI1. Coexpression of ADAM22 strongly reduced AB060-203
binding to LGI1. (D) AB060-203 efficiently blocked ADAM22 binding to LGI1. ELISA signals (mean ± SD from 4 wells) indicate
binding of the extracellular domain of ADAM22 (ADAMexHA) to LGI1-Fc after preincubation with purified monoclonal human
(Figure legend continues on next page.)
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extracellular domain of ADAM22 bound to immobilized
LGI1 on 96-well plates. Pretreatment of LGI1 with seven of
the monoclonal LGI1 antibodies reduced ADAM22-binding
by >60% (Fig 2). Interestingly, each of the 3 patients’ CSF
samples contained ASCs expressing ADAM22-competing
and ASCs expressing ADAM22-noncompeting antibodies,
confirming the polyclonal nature of the LGI1 autoimmune
response predicted earlier.31 We selected and purified 2 LGI1
antibodies derived from ASCs of Patient AIE060, 1 interfering
with the LGI1–ADAM22 interaction (AB060-203) and
1 that did not (AB060-110), and tested their LGI1 selectivity
and ADAM competition in detail.
Immunohistochemistry on mouse brain sections of
wild-type and Lgi1 knockout mice proved that both of
these antibodies recognize LGI1 selectively (Fig 3). How-
ever, although their concentration-dependent binding cur-
ves pointed to comparable binding efficiencies in the
LGI1 ELISA, AB060-203, which efficiently competed
with the soluble extracellular domain of ADAM22 for
LGI1-binding, resulted in much weaker signals on mouse
brain sections than AB060-110. Immunocytochemistry on
COS7 cells confirmed a selective recognition of surface-
expressed LGI1, but not LGI2 or LGI3 by both
AB060-110 and AB060-203. Interestingly, LGI1 detec-
tion by AB060-203, but not by AB060-110, was strongly
reduced in COS7 cells coexpressing LGI1 and ADAM22.
Thus, the LGI1 epitope recognized by AB060-203 can be
masked by ADAM22. LGI1-binding by AB060-203 may
be blocked by ADAM22 in vivo, and this may account
for the reduced signals of AB060-203 against native
LGI1. To test whether blockade of ADAM22-binding to
LGI1 in the ELISA (see Fig 2) correlated with a reduced
access to endogenous LGI1 in the brain in general, we
determined the immunohistochemistry staining signal of
all monoclonal LGI1 antibodies on mouse brain sections.
Although the range of signals was wide, the group of anti-
bodies that had reduced ADAM22-binding by >60% in
the ELISA (see Fig 2) resulted in lower LGI1 binding
than the remaining group (see Fig 3E). Thus, it appears
that antibodies that compete with ADAM proteins for
antibodies. The amount of human antibodies bound to LGI1-Fc was not affected by the ADAMexHA application in this setting
(AB060-110: 93 ± 8%, mean ± SD, of human IgG bound without ADAMexHA application; AB060-203: 100 ± 10%). (E) Antibodies
that interfere with ADAM22 binding to LGI1 have limited access to native LGI1. Relative quantification of the binding strength in
hippocampal area CA3 of all human monoclonal LGI1 antibodies (mean ± SEM) revealed higher mean fluorescent intensities
(MFIs) for the non–ADAM22-competing group than for the ADAM22-competing group (unpaired t test, p < 0.0001, n = 7 and
17). Left: Example analysis with 2 antibodies. Human IgG is shown in red, nuclei (DAPI) in blue. Scale bar = 100μm. In the scatter
plot, these examples are highlighted in red.
FIGURE 4: Human monoclonal antibodies AB060-110 and AB060-203 target different domains of LGI1. AB060-110 selectively
recognized the leucine-rich repeat (LRR) domain of LGI1, whereas AB060-203 detected the epitempin (EPTP) repeat domain and
weakly the LRR domain of LGI1. Schemes of chimeric constructs expressed to determine the target epitopes in LGI1 are shown
on top. (A) COS7 cells expressing chimera of LGI1 and LGI3 were analyzed as in Figure 3C. Scale bar = 20μm. (B) Enzyme-linked
immunosorbent assay signals of purified antibodies at 1μg/ml on LGI1-Fc, LGI2-Fc, or chimera thereof. Signals are shown as
mean ± SD from 3 wells.
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FIGURE 5: AB060-110 and AB060-203 increased the excitability of CA3 pyramidal neurons in hippocampal slice cultures. (A–E)
Example traces of cell responses during depolarizing current steps (top: +160pA, middle: +120pA, bottom: +80pA) in CA3
pyramidal cells. Scale bars correspond to 20mV/160pA and 0.1 second. Slice cultures were left untreated (A), were treated with
antibodies AB060-110 (B), AB060-203 (C), or AB060-144 (D), or were incubated with dendrotoxin-K (DTX-K; E). (F) Spike
number/current intensity relationship displays a significant increase in spike number when slices were preincubated with
AB060-110 or AB060-203. Two-way analysis of variance, control versus AB060-110: 200pA, p < 0.05; 240pA, p < 0.01; 280pA,
p < 0.001; 320pA, p < 0.001. Control versus AB060-203: 240pA, p < 0.01; 280pA, p < 0.001; 320pA, p < 0.001. Control versus
AB060-144: not significant (n.s.). AB060-110 versus AB060-203: n.s. AB060-144 versus AB060-110: 160pA, p < 0.05; 200pA,
p < 0.001; 240pA, p < 0.001; 280pA, p < 0.001; 320pA, p < 0.001. AB060-203 versus AB060-144: 200pA, p < 0.01; 240pA,
p < 0.001; 280pA, p < 0.001; 320pA, p < 0.001. (G) The number of spikes that were elicited by 280pA current injection was
significantly higher in AB060-110–treated slices. ANOVA: p = 0.0011. (H) The rheobase was significantly reduced in cells that
were preincubated with AB060-110 or with DTX-K. ANOVA: p < 0.0001. (I) The action potential (AP) threshold was significantly
reduced in cells that were preincubated with AB060-110 or DTX-K. ANOVA: p = 0.0151. (J, K) The resting membrane potential
(RMP; J) and the whole cell capacitance (K) were not altered in the different treatment conditions. Number of cells (F-K): control,
n = 37; AB060-110, n = 36; AB060-203, n = 38; AB060-144, n = 37; DTX-K, n = 33. (L) The slope of the slowly depolarizing ramp
at subthreshold stimulation intensities was significantly reduced in cells that were preincubated with AB060-110 or DTX-K.
ANOVA: p < 0.0001. Control, n = 39; AB060-110, n = 39; AB060-203, n = 38; AB060-144, n = 37; DTX-K, n = 32. (M) Acute
wash-in of 100nM DTX-K reduced the slope of the depolarizing ramp in control, AB060-203, and in AB060-144 conditions,
(Figure legend continues on next page.)
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binding to LGI1 have limited access to their targets in
native tissue or reach their targets only after long exposi-
tion times, for example, upon turnover of ADAM-LGI1
complexes. Previous studies suggested that ADAM-
competing and ADAM-noncompeting LGI1 antibodies
bind to different domains in LGI1.31 Expression of chi-
meric LGI1/3 and LGI1/2 constructs (Fig 4) revealed that
AB060-110 selectively recognized the LRR domain of
LGI1. In contrast, AB060-203 primarily bound to the
EPTP repeat domain that mediates interactions of LGI1
with ADAM family proteins14 and, weakly, to the LRR
domain of LGI1 (see Fig 4). Taken together, AB060-203
targeted the EPTP repeat domain of LGI1, competed with
ADAM22 binding, and showed reduced binding to native
LGI1. In contrast, AB060-110 bound to the LRR domain
of LGI1 and appeared to be much less affected by
ADAM22, predicting efficient access of this antibody to
LGI1-ADAM complexes in vivo.
Human Monoclonal LGI1 Antibodies Elicit
Increased Intrinsic Excitability and Synaptic
Transmission of Hippocampal CA3 Neurons
LGI1 mutations cause ADPEAF in humans, and targeted
deletion of Lgi1 in mice resulted in lethal myoclonic
epileptic seizures.18–20 The intrinsic excitability of CA3
neurons in hippocampal slice cultures was decreased by
recombinant LGI1 and increased by genetic deletion of
Lgi1.21 Furthermore, acute application of IgG prepara-
tions from the sera of limbic encephalitis patients,
potentially containing LGI1 antibodies, enhanced the
excitability of CA3 pyramidal neurons in hippocampal
slices.22 Given the known link between CA3 excitability
and seizure generation, we wanted to test whether these
effects can be caused by LGI1 antibodies from the CSF of
limbic encephalitis patients. Hippocampal slice cultures
were treated with purified recombinant human IgG1 anti-
body AB060-110, AB060-203, or AB060-144 as a non–
LGI1-reactive control (see Fig 1P, Q) for 24 to 48 hours,
and the intrinsic excitability of CA3 pyramidal cells was
examined (Fig 5). Patch clamp recordings were per-
formed to determine the cells’ excitability by injecting
depolarizing currents (1 second, 40pA increment)
under current clamp configuration and counting the
numbers of generated APs. Treatment with AB060-110
or AB060-203 robustly increased cell excitability, with
decreases in rheobase and AP thresholds at more
hyperpolarized membrane potentials. In contrast,
treatment with control antibody AB060-144 did not
change cell excitability, rheobase, or AP threshold. The
effects of AB060-110 were more pronounced than the
effects of AB060-203, in accord with their differences in
epitope access (see Fig 3). Both resting membrane poten-
tial and capacitance of the CA3 cells were unchanged by
antibody treatment (see Fig 5). Lgi1 deletion has been
shown to reduce the axonal density of Kv1.1/1.2 channels
that limit glutamate release,21 and we wondered whether
LGI1 antibodies augmented neuronal excitability through
this pathway also. The slowly depolarizing ramp elicited
by subthreshold depolarization steps that represents a hall-
mark of the D-type potassium current36 and is induced by
Kv1 channels37 was efficiently reduced by AB060-110,
mimicking the effect of DTX-K, a selective antagonist of
Kv1.1-containing potassium channels. As expected,21,38
DTX-K increased the intrinsic cellular excitability of CA3
cells as well, similar to AB060-110. Furthermore,
although an acute wash-in of DTX-K significantly reduced
Kv1 currents in CA3 cells that had been treated with con-
trol antibody AB060-144 for 24 hours, the effect of
DTX-K was occluded by prior treatment with LGI1 anti-
body AB060-110. These data indicate that LGI1 anti-
bodies increase the intrinsic excitability of CA3 cells by
reducing Kv1 currents.
We next set out to test whether LGI1 antibodies
elicited AP-independent changes in synapses on CA3 cells
as well. Application of LGI1 antibodies to hippocampal
slice cultures for 24 hours significantly increased the
amplitudes and the frequency (significantly different in
the cumulative frequency distribution of the IEIs) of
AMPAR mEPSCs (Fig 6). As in the measurements of the
intrinsic cellular excitability, LGI1 antibody AB060-203
elicited a smaller effect than AB060-110, but showed the
same tendency. Treatment of hippocampal slice cultures
with DTX-K for 24 hours shifted the mEPSC distribution
to higher amplitudes as well. Thus, LGI1 antibodies
increased cellular excitability and synaptic transmission of
CA3 neurons, and both effects may be explained by a
downregulation of axonal Kv1 currents.
Together, these data show that the addition of single
patient-derived monoclonal antibodies was sufficient to
interfere with LGI1 function that may be causal for LGI1
encephalitis symptoms. In addition, the profound effects
of AB060-110 demonstrate that LGI1 antibodies can elicit
hyperexcitability without direct interference with LGI1-
ADAM interactions.
whereas treatment with AB060-110 occluded the reduction of the D-current by DTX-K. Paired t test with Bonferroni multiple
comparison correction before versus after DTX-K: control, p = 0.0064; AB060-110, p = 0.56; AB060-203, p = 0.024; AB060-144,
p = 0.0104. Control, n = 8; AB060-110, n = 8; AB060-203, n = 9; AB060-144, n = 7. Data is shown as mean with SEM. Dunn
multiple comparison correction was performed in G-L. Significance levels: *p < 0.05; **p < 0.01; ***p < 0.001.
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Discussion
Here, we provide insight into the antibody repertoire in
the brain of LGI1 encephalitis patients by sequencing and
cloning immunoglobulins expressed in CSF B cells and
ASCs. A previous analysis of the antibody repertoire in
NMDA receptor encephalitis revealed that only a small
fraction of antibodies expressed by ASCs were directed to
the NMDA receptor, and the majority of non–NMDA
receptor-reactive antibodies targeted other brain epi-
topes.25 Furthermore, the number of somatic hyper-
mutations in the V genes of NMDA receptor
autoantibodies among all patients was significantly lower
compared to CSF antibodies not targeting the NMDA
receptor of the same patients.25 The NMDA receptor
encephalitis repertoire contained antibodies lacking any
mutation as compared to the germline sequence.25,30 Our
findings in LGI1 encephalitis are in striking contrast. First,
in LGI1 encephalitis, the fraction of ASCs expressing LGI1
antibodies was high. Second, reactions to brain antigens
other than LGI1 were rare. Third, the V gene sequences
for the heavy and light chains of the LGI1 antibodies con-
tained many mutations as compared to the germline
sequence, particularly in Patient AIE054. Together with
the finding that LGI1 encephalitis but not NMDA recep-
tor encephalitis is strongly associated with specific human
leukocyte antigen haplotypes,10–13 these data indicate fun-
damental differences between the 2 most common AIEs.
They may represent an immunological basis reflecting the
clinical diversity between the 2 diseases, including not only
etiology, age and gender preferences, and tumor associa-
tions, but also clinical courses and treatment responses.
Patients with LGI1 encephalitis, like the patients
examined here, frequently have normal CSF cell counts
and protein levels and no oligoclonal IgG bands. The
presence of LGI1 antibody-producing cells in the CSF of
all 3 investigated CSF samples in this study, although only
1 of them had oligoclonal IgG bands and only 1 other
had LGI1 antibody detectable in routine cell-based assays,
proves that these patients also have an intrathecal LGI1
autoantibody production. Antibodies against brain targets
FIGURE 6: AB060-110 and AB060-203 increased α-amino-
3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor
miniature excitatory postsynaptic currents in CA3 pyramidal
neurons in hippocampal slice cultures. (A) Example traces of
miniature events recorded from CA3 cells in the presence of
tetrodotoxin, gabazine, and D-AP5. Scale bar corresponds to
5pA and 10 milliseconds. (B) Sample traces of miniature
excitatory postsynaptic currents (mEPSCs). Scale bar
corresponds to 10pA and 500 milliseconds. (C) The mean
amplitude of mEPSCs was significantly larger after 24-hour
incubation with LGI1 antibody AB060-110 than after
incubation with control antibody AB060-144. ANOVA:
p = 0.0111. DTX-K = dendrotoxin-K. (D) Cumulative
frequency distribution of mEPSC amplitudes was shifted to
the right, indicating larger mEPSC amplitudes after
incubation with LGI1 antibodies as compared to control
antibody AB060-144. Control versus AB060-110: p = 0.0042;
control versus AB060-203: p = 0.003; control versus
AB060-144: p = 1; control versus DTX-K: p = 0.0006;
AB060-144 versus AB060-110: p = 0.003; AB060-144 versus
AB060-203: p = 0.0042. (E) The mean mEPSC frequency was
not changed significantly by LGI1 antibodies. ANOVA:
p = 0.109. (F) Cumulative frequency distribution of mEPSC
(Figure legend continues on next page.)
interevent intervals (IEIs) was shifted to the left, indicating
shorter intervals after incubation with LGI1 antibodies as
compared to control antibody AB060-144. Control versus
AB060-110: p = 1; control versus AB060-203: p = 1; control
versus AB060-144: p = 0.4242; control versus DTX-K: p = 1;
AB060-144 versus AB060-110: p = 0.0054; AB060-144 versus
AB060-203: p = 0.0294. Number of cells: control, n = 23;
AB060-110, n = 21; AB060-203, n = 20; AB060-144, n = 21;
DTX-K, n = 20. Data is shown as mean + SEM (C,E). Dunn
multiple comparison correction was performed in C, E;
Kolmogorov-Smirnov test with Bonferroni multiple comparison
correction was performed in D, F. Significance levels: *p <
0.05; **p < 0.01; ***p < 0.001.column.)
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may escape detection within the CSF, as they quickly bind
to their antigens.39 This raises the question of whether
intense immunotherapy may be required also in patients
with low-level antibodies and a compatible clinical picture
and, even more intriguing, whether undetectable levels in
routine assays may still account for slowly progressing cog-
nitive decline in a small fraction of patients with atypical
dementia, given that cases with LGI1 antibody-associated
dementia are increasingly reported.40,41
Hippocampal CA3 neurons are a frequent focus of sei-
zure generation, and their intrinsic excitability was increased
by genetic deletion of Lgi1 through downregulation of axo-
nal Kv1 potassium channels.21 Kv1 channel inactivation at
the axon initial segment is known to result in AP broaden-
ing, increased synaptic strength, and neuronal hyper-
excitability.38,42,43 We show that isolated recombinant LGI1
antibodies increase the intrinsic excitability of hippocampal
CA3 neurons by reducing Kv1 currents as well. This finding
supports the view that antibodies are directly pathogenic in
LGI1 encephalitis. The antibody-induced neuronal overex-
citation may explain seizure symptoms in LGI1 encephalitis,
including FBDS and focal and generalized seizures, which
are often followed by cognitive impairment if not suffi-
ciently treated with immunosuppression.44 Also, we show
an LGI1 antibody-elicited increase in AMPAR mEPSC
amplitude and frequency in CA3 neurons of hippocampal
slice cultures that may rely on reduced Kv1 currents as well.
Together, LGI1 antibodies increase intrinsic cellular excit-
ability and glutamatergic transmission, and both effects may
contribute to seizure generation in LGI1 encephalitis. Ste-
reotactic injection of human CSF containing LGI1 anti-
bodies into the dorsal hippocampus of mice increased the
probability of glutamate release at CA3–CA1 synapses, but
did not alter the intrinsic excitability of CA1 cells.24 CA1
pyramidal neurons may be less sensitive to LGI1 antibodies
than CA3 neurons due to their low level of Kv1.1.45,46
Targeted deletion of Lgi1 altered AMPAR-mediated
synaptic transmission in CA1 neurons. Increased mEPSC
amplitudes were detected in acute slices of Lgi1 null mice
at P8/9, in line with a stronger glutamatergic drive onto
CA1 neurons.47 In contrast, in acute hippocampal slices
of P14/15 mice lacking Lgi1, decreased mEPSC ampli-
tudes and a reduced AMPA/NMDA ratio indicated post-
synaptic effects.19 Similar results were observed in CA1 or
dentate gyrus granule cells from cultured hippocampal
slices prepared from Lgi1 null mice at P6–8 before seizure
onset.16 The reason for these discrepancies is not known,
but additional experiments indicated that LGI1 promotes
postsynaptic maturation through ADAM22 and PSD-
95.16 Antibody-mediated interference with the LGI1–
ADAM22–PSD-95 link is expected to alter the composi-

























































The patients show typical features of LGI1 encephalitis, such as older age, mesiotemporal MRI changes, and noninflammatory CSF.
Ab = antibody; AED = antiepileptic drug; AIE = autoimmune encephalopathy; CSF = cerebrospinal fluid; F = female; FBDS = faciobrachial dystonic
seizures; IA = immunoadsorption; IVIG = intravenous immunoglobulins; M = male; MP = methylprednisolone; MRI = magnetic resonance imaging;
MTX = methotrexate; neg. = negative; OCB = oligoclonal bands; pos. = positive; Pred = prednisolone; S = serum.
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in deficient AMPAR recruitment14,16,23,31 and underlie
cognitive deficits in LGI1 encephalitis. It is possible that
the inhibitory effects of LGI1 antibodies are limited by
the accessibility of mature synaptic structures and are
detected only after long exposition times.
Because several unavoidable autoreactive in vivo
mechanisms, such as complement activation and inflam-
matory processes, are not active in slice cultures, the
observed effects of LGI1 antibodies AB060-110 and
AB060-203 are most likely mediated by direct binding
to their respective epitopes. It was reported that sera of
patients with LGI1 encephalitis cause LGI1-ADAM22
complex internalization in transfected HEK293T cells,44
suggesting downregulation of LGI1-ADAM22 com-
plexes as a pathogenic mechanism of LGI1 antibodies.
The same mechanism that autoantibodies extracellularly
bind to target proteins and cause their selective internali-
zation was reported for autoantibodies to NMDA recep-
tors48 and to AMPARs.49 In contrast, recent structural
analyses revealed higher-order LGI1-ADAM complexes
with 2:2 or 3:3 configurations.15 LGI1 antibodies like
AB060-110 may interfere with LRR domain interactions
and thereby destabilize these complexes. Other LGI1 anti-
bodies like AB060-203 are thought to prevent or disrupt
LGI1-ADAM interactions. Given that ADAM22/23 in
Lgi1 knockout mouse brain was delocalized from synaptic
fractions,19 ADAM22/23 unbound from LGI1 due to
LGI1 antibodies might be rapidly internalized from synap-
tic membranes. Thus, irrespective of the target epitope and
their direct mode of action, LGI1 antibodies may elicit a
reduction in the number of LGI1-ADAM complexes from
synaptic membranes. Antibodies targeting different LGI1
epitopes may act in synergy in patients’ CSF. In any case,
the functional effects of monoclonal LGI1 antibodies dem-
onstrated here indicate direct pathogenicity in LGI1
encephalitis and provide the rationale for clinicians for suffi-
ciently "aggressive" immunotherapy and second-line or pro-
longed treatment in relapsing or slowly progressing cases.
Although immunotherapy is fast and efficient in
some LGI1 encephalitis patients, other cases are character-
ized by a long and continuously progressing disease pro-
cess, including memory deficits, apathy, and difficulties
with spatial orientation.4 Recent studies indicated that a
high CSF index and specific IgG isotypes might be predic-
tive of refractory symptoms and cognitive impairment.9,44
In a patient with a long-lasting progressive LGI1 encepha-
litis (AIE060), our screen detected LGI1 antibodies of
IgG1, IgG2, and IgG4 subtype in CSF ASCs and MBCs.
In contrast, in Patient AIE054, we found exclusively anti-
bodies of IgG2 isotype in ASCs. It should be examined in
larger cohorts whether the presence of IgG1 or IgG4 anti-
bodies is predictive of cases with severe, long-lasting
disease courses. The monoclonal antibodies described here
will be helpful in testing these and other hypotheses and
in developing refined diagnostics.
Acknowledgment
This study was supported by the German Research Foun-
dation (SFB 958, 1315, FOR 3004, SPP 1665, Exc
257 to D.S.; PR 1274/2-1, PR 1274/3-1 to H.P.),
Helmholtz Association (Helmholtz ExNet-0009-Phase 2-3
NeuroCure to D.S.), Federal Ministry of Education and
Research (SMARTAGE 01GQ1420A to D.S.), Charité
Foundation to D.S., JSPS/MEXT KAKENHI (19H03331
to Y.F.; 17H03678, 19K22548 to M.F.), Hori Sciences
and Arts Foundation to M.F., Japan Epilepsy Research
Foundation to Y.F., and Daiko Foundation to Y.F.
We thank D. Brandl, S. Stadler, P. Loge, and
S. Rieckmann for excellent technical assistance, T. Frey
for characterization of GluN1-ATD-Fc, J. Schlender for
help with stainings, B. Rost for help with slice cultures,
and R. Murugan for advice.
Author Contributions
H.-C.K., M.F., H.P., and D.S. contributed to the concep-
tion and design of the study; H.-C.K., J.K., A.S., Y.F., D.P.,
R.P.S., B.I., S.K., A.B.K., and M.F. contributed to the
acquisition and analysis of data; H.-C.K., J.K., A.S., and
H.P. contributed to drafting the text and preparing the
figures.
Potential Conflicts of Interest
Nothing to report.
References
1. Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium
channel-complex proteins leucine-rich, glioma inactivated 1 protein
and contactin-associated protein-2 in limbic encephalitis, Morvan’s
syndrome and acquired neuromyotonia. Brain 2010;133:2734–2748.
2. Lai M, Huijbers MG, Lancaster E, et al. Investigation of LGI1 as the
antigen in limbic encephalitis previously attributed to potassium
channels: a case series. Lancet Neurol 2010;9:776–785.
3. Dalmau J, Geis C, Graus F. Autoantibodies to synaptic receptors and
neuronal cell surface proteins in autoimmune diseases of the central
nervous system. Physiol Rev 2017;97:839–887.
4. van Sonderen A, Petit-Pedrol M, Dalmau J, et al. The value of LGI1,
Caspr2 and voltage-gated potassium channel antibodies in encepha-
litis. Nat Rev Neurol 2017;13:290–301.
5. Crisp SJ, Kullmann DM, Vincent A. Autoimmune synaptopathies. Nat
Rev Neurosci 2016;17:103–117.
6. Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med
2018;378:840–851.
7. Irani SR, Michell AW, Lang B, et al. Faciobrachial dystonic seizures
precede Lgi1 antibody limbic encephalitis. Ann Neurol 2011;69:
892–900.
March 2020 417
Kornau et al: LGI1 Encephalitis Antibodies
8. Finke C, Pruss H, Heine J, et al. Evaluation of cognitive deficits and
structural hippocampal damage in encephalitis with leucine-rich,
glioma-inactivated 1 antibodies. JAMA Neurol 2017;74:50–59.
9. Gadoth A, Zekeridou A, Klein CJ, et al. Elevated LGI1-IgG CSF index
predicts worse neurological outcome. Ann Clin Transl Neurol 2018;5:
646–650.
10. Binks S, Varley J, Lee W, et al. Distinct HLA associations of LGI1 and
CASPR2-antibody diseases. Brain 2018;141:2263–2271.
11. Kim TJ, Lee ST, Moon J, et al. Anti-LGI1 encephalitis is associated
with unique HLA subtypes. Ann Neurol 2017;81:183–192.
12. van Sonderen A, Roelen DL, Stoop JA, et al. Anti-LGI1 encephalitis
is strongly associated with HLA-DR7 and HLA-DRB4. Ann Neurol
2017;81:193–198.
13. Mueller SH, Farber A, Pruss H, et al. Genetic predisposition in anti-LGI1
and anti-NMDA receptor encephalitis. Ann Neurol 2018;83:863–869.
14. Fukata Y, Adesnik H, Iwanaga T, et al. Epilepsy-related
ligand/receptor complex LGI1 and ADAM22 regulate synaptic trans-
mission. Science 2006;313:1792–1795.
15. Yamagata A, Miyazaki Y, Yokoi N, et al. Structural basis of epilepsy-
related ligand-receptor complex LGI1-ADAM22. Nat Commun 2018;
9:1546.
16. Lovero KL, Fukata Y, Granger AJ, et al. The LGI1-ADAM22 protein
complex directs synapse maturation through regulation of PSD-95
function. Proc Natl Acad Sci U S A 2015;112:E4129–E4137.
17. Schulte U, Thumfart JO, Klocker N, et al. The epilepsy-linked Lgi1
protein assembles into presynaptic Kv1 channels and inhibits inacti-
vation by Kvbeta1. Neuron 2006;49:697–706.
18. Yu YE, Wen L, Silva J, et al. Lgi1 null mutant mice exhibit myoclonic
seizures and CA1 neuronal hyperexcitability. Hum Mol Genet 2010;
19:1702–1711.
19. Fukata Y, Lovero KL, Iwanaga T, et al. Disruption of LGI1-linked syn-
aptic complex causes abnormal synaptic transmission and epilepsy.
Proc Natl Acad Sci U S A 2010;107:3799–3804.
20. Chabrol E, Navarro V, Provenzano G, et al. Electroclinical characteri-
zation of epileptic seizures in leucine-rich, glioma-inactivated
1-deficient mice. Brain 2010;133:2749–2762.
21. Seagar M, Russier M, Caillard O, et al. LGI1 tunes intrinsic excitability
by regulating the density of axonal Kv1 channels. Proc Natl Acad Sci
U S A 2017;114:7719–7724.
22. Lalic T, Pettingill P, Vincent A, et al. Human limbic encephalitis
serum enhances hippocampal mossy fiber-CA3 pyramidal cell synap-
tic transmission. Epilepsia 2011;52:121–131.
23. Petit-Pedrol M, Sell J, Planaguma J, et al. LGI1 antibodies alter
Kv1.1 and AMPA receptors changing synaptic excitability, plasticity
and memory. Brain 2018;141:3144–3159.
24. Romoli M, Krashia P, Sen A, et al. Hippocampal epileptogenesis in
autoimmune encephalitis. Ann Clin Transl Neurol 2019;6:2261–2269.
25. Kreye J, Wenke NK, Chayka M, et al. Human cerebrospinal fluid
monoclonal N-methyl-D-aspartate receptor autoantibodies are suffi-
cient for encephalitis pathogenesis. Brain 2016;139:2641–2652.
26. Malviya M, Barman S, Golombeck KS, et al. NMDAR encephalitis:
passive transfer from man to mouse by a recombinant antibody. Ann
Clin Transl Neurol 2017;4:768–783.
27. Tiller T, Meffre E, Yurasov S, et al. Efficient generation of monoclonal
antibodies from single human B cells by single cell RT-PCR and
expression vector cloning. J Immunol Methods 2008;329:112–124.
28. Wardemann H, Yurasov S, Schaefer A, et al. Predominant autoanti-
body production by early human B cell precursors. Science 2003;
301:1374–1377.
29. Murugan R, Buchauer L, Triller G, et al. Clonal selection drives pro-
tective memory B cell responses in controlled human malaria infec-
tion. Sci Immunol 2018;3. pii: eaap8029.
30. Wenke NK, Kreye J, Andrzejak E, et al. N-methyl-D-aspartate recep-
tor dysfunction by unmutated human antibodies against the NR1
subunit. Ann Neurol 2019;85:771–776.
31. Ohkawa T, Fukata Y, Yamasaki M, et al. Autoantibodies to epilepsy-
related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interac-
tion and reduce synaptic AMPA receptors. J Neurosci 2013;33:
18161–18174.
32. Rost BR, Schneider F, Grauel MK, et al. Optogenetic acidification of
synaptic vesicles and lysosomes. Nat Neurosci 2015;18:1845–1852.
33. Gray D. A role for antigen in the maintenance of immunological
memory. Nat Rev Immunol 2002;2:60–65.
34. Arino H, Armangue T, Petit-Pedrol M, et al. Anti-LGI1-associated
cognitive impairment: presentation and long-term outcome. Neurol-
ogy 2016;87:759–765.
35. Irani SR, Pettingill P, Kleopa KA, et al. Morvan syndrome: clinical and
serological observations in 29 cases. Ann Neurol 2012;72:241–255.
36. Storm JF. Temporal integration by a slowly inactivating K+ current in
hippocampal neurons. Nature 1988;336:379–381.
37. Metz AE, Spruston N, Martina M. Dendritic D-type potassium cur-
rents inhibit the spike afterdepolarization in rat hippocampal CA1
pyramidal neurons. J Physiol 2007;581:175–187.
38. Bekkers JM, Delaney AJ. Modulation of excitability by alpha-den-
drotoxin-sensitive potassium channels in neocortical pyramidal neu-
rons. J Neurosci 2001;21:6553–6560.
39. Castillo-Gomez E, Kastner A, Steiner J, et al. The brain as
immunoprecipitator of serum autoantibodies against N-methyl-D-
aspartate receptor subunit NR1. Ann Neurol 2016;79:144–151.
40. Marquetand J, van Lessen M, Bender B, et al. Slowly progressive
LGI1 encephalitis with isolated late-onset cognitive dysfunction: a
treatable mimic of Alzheimer’s disease. Eur J Neurol 2016;23:
e28–e29.
41. Reintjes W, Romijn MD, Hollander D, et al. Reversible dementia: two
nursing home patients with voltage-gated potassium channel
antibody-associated limbic encephalitis. J Am Med Dir Assoc 2015;
16:790–794.
42. Geiger JR, Jonas P. Dynamic control of presynaptic Ca(2+) inflow by
fast-inactivating K(+) channels in hippocampal mossy fiber boutons.
Neuron 2000;28:927–939.
43. Kole MH, Letzkus JJ, Stuart GJ. Axon initial segment Kv1 channels
control axonal action potential waveform and synaptic efficacy. Neu-
ron 2007;55:633–647.
44. Thompson J, Bi M, Murchison AG, et al. The importance of early
immunotherapy in patients with faciobrachial dystonic seizures. Brain
2018;141:348–356.
45. Kues WA, Wunder F. Heterogeneous expression patterns of mam-
malian potassium channel genes in developing and adult rat brain.
Eur J Neurosci 1992;4:1296–1308.
46. Rhodes KJ, Strassle BW, Monaghan MM, et al. Association and
colocalization of the Kvbeta1 and Kvbeta2 beta-subunits with Kv1
alpha-subunits in mammalian brain K+ channel complexes.
J Neurosci 1997;17:8246–8258.
47. Boillot M, Lee CY, Allene C, et al. LGI1 acts presynaptically to regu-
late excitatory synaptic transmission during early postnatal develop-
ment. Sci Rep 2016;6:21769.
48. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic
mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;
30:5866–5875.
49. Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic
encephalitis alter synaptic receptor location. Ann Neurol 2009;65:
424–434.
418 Volume 87, No. 3
ANNALS of Neurology
